| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K49290616 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.7 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | Platin | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.7 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.7 |
| mRNA | BRD-K16130065 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.7 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | fulvestrant | CTRPv2 | pan-cancer | AAC | -0.028 | 0.7 |
| mRNA | BRD-K84807411 | CTRPv2 | pan-cancer | AAC | -0.026 | 0.7 |